AIM ImmunoTech Inc.
AIM · Healthcare · $6M
After-hours $0.17-0.63%
Price
$0.28
$0.18
Jun 30, 26Sep 28, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$0M-1.0%
6/'26 vs prev quarter
Company Health
Market Cap$6M
Cash on Hand$10M155.8% of market cap
Free Cash Flow$-7M-112.7% of market cap
Among 326 Biotechnology peers
LowMedianHigh
PSR6.6xmedian 11.1xPBR0.1xmedian 2.0xROE-184.3%median -54.5%AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner VideoSep 9
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041Sep 2
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039Aug 31
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand ConferenceAug 27
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' ArticleAug 12
AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection PointAug 3
